Q-omics provides the consensus-scored RPN2 profile across patient tissues and cancer cell-line models. RPN2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RPN2 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, RPN2 protein abundance shows 24,747 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where RPN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPN2 survival associations across molecular data types. RPN2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPN2 RNA expression–survival associations across cancer types. High RPN2 expression shows unfavorable associations in MESO, BLCA, UVM, LIHC, ACC and KICH. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RPN2 RNA expression.
This table summarizes RPN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RPN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPN2 shows higher tumor expression in HNSC, KIRC, COAD, BLCA, STAD and LIHC. The HNSC box plot shows higher RPN2 RNA expression in tumor versus normal tissue (log2 FC = +1.258, t-test p < 0.001).
This table shows molecular features associated with RPN2 in patient tissues and cancer cell lines. In patient samples, RPN2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and CNS.
